Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss

Viking Therapeutics' obesity candidate VK2735 advanced to Phase 3 after Phase 2 data showed approximately 15% weight loss from baseline after 13 weeks at the highest tested dose. The clinical progression and efficacy result materially strengthen VK2735's position in the high-growth obesity-drug market, with likely meaningful implications for VKTX shares.